Clinical Trial Update: Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients [Phase 2]

View source ↗

Summary

This document reports a Phase 2 clinical trial evaluating nanoliposomal irinotecan (Nal-IRI) with 5-FU and leucovorin, combined with a PD-L1 inhibitor and a mul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Leucovorin (folinic acid)
• Multi-target anti-angiogenic small molecule
• Onivyde (nal-IRI) (nanoliposomal irinotecan)
• PD-L1 inhibitor (Programmed death-ligand 1 inhibitor)

Snippet

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Conditions: Advanced Metastatic Pancreatic Cancer | Phase 2 | Status: RECRUITING